GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (FRA:I7G) » Definitions » Quality Rank

Ipsen (FRA:I7G) Quality Rank


View and export this data going back to 2005. Start your Free Trial

What is Ipsen Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Ipsen Quality Rank Related Terms

Thank you for viewing the detailed overview of Ipsen's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Ipsen (FRA:I7G) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (FRA:I7G) » Definitions » Quality Rank
Comparable Companies
XPAR:VETO XPAR:BOI XPAR:EAPI XPAR:AB XPAR:MLCOT XPAR:ALRPD XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB BOM:532321 TSE:4507 HKSE:03692 VTRS
Traded in Other Exchanges
IPSEY:USA IPSEF:USA 0MH6:UK IPN:France I7G:Germany
Address
65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100
Website
https://www.ipsen.com
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.